Neuroimmunology of Huntington's Disease: Revisiting Evidence from Human Studies

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Rocha, Natalia P ^a   Ribeiro, Fabiola M ^b   Furr Stimming, Erin ^a   Teixeira, Antonio L ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CANNABINOID; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; LAQUINIMOD; MINOCYCLINE; NABILONE; UNCLASSIFIED DRUG; VX 15; VX 2503; XPRO 1595;

CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; DISEASE COURSE; HUMAN; HUNTINGTON CHOREA; IMMUNOCOMPETENT CELL; INTRACELLULAR SIGNALING; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROIMMUNOLOGY; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; POSITRON EMISSION TOMOGRAPHY; REVIEW; DRUG EFFECTS; HUNTINGTON DISEASE; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY;

ANTI-INFLAMMATORY AGENTS; CENTRAL NERVOUS SYSTEM; CYTOKINES; HUMANS; HUNTINGTON DISEASE; INFLAMMATION; PERIPHERAL NERVOUS SYSTEM;

EID: 84983762705     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/8653132     Document Type: Review

References (61)

1. C. A. Ross and S. J. Tabrizi, "Huntington's disease: from molecular pathogenesis to clinical treatment," The Lancet Neurology, vol. 10, no. 1, pp. 83-98, 2011.
2. The Huntington's Disease Collaborative Research Group, "A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes," Cell, vol. 72, no. 6, pp. 971-983, 1993.
3. F. Cardoso, "Huntington disease and other choreas," Neurologic Clinics, vol. 27, no. 3, pp. 719-736, 2009.
4. E. Cattaneo, C. Zuccato, and M. Tartari, "Normal huntingtin function: an alternative approach to Huntington's disease," Nature Reviews Neuroscience, vol. 6, no. 12, pp. 919-930, 2005.
5. A. J. Tobin and E. R. Signer, "Huntington's disease: the challenge for cell biologists," Trends in Cell Biology, vol. 10, no. 12, pp. 531-536, 2000.
6. A. Crotti and C. K. Glass, "The choreography of neuroinflammation in Huntington's disease," Trends in Immunology, vol. 36, no. 6, pp. 364-373, 2015.
7. D. K. Kaushik andA. Basu, "Afriendinneedmaynotbe a friend indeed: role of microglia in neurodegenerative diseases," CNS & Neurological Disorders-Drug Targets, vol. 12, no. 6, pp. 726-740, 2013.
8. M. Björkqvist, E. J. Wild, J. Thiele et al., "A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease,"The Journal of Experimental Medicine, vol. 205, no. 8, pp. 1869-1877, 2008.
9. R. H. Myers, J. P. Vonsattel, P. A. Paskevich et al., "Decreased neuronal and increased oligodendroglial densities in huntington's disease caudate nucleus," Journal of Neuropathology and Experimental Neurology, vol. 50, no. 6, pp. 729-742, 1991.
10. E. Sapp, K. B. Kegel, N. Aronin et al., "Early and progressive accumulation of reactive microglia in the Huntington disease brain," Journal of Neuropathology and Experimental Neurology, vol. 60, no. 2, pp. 161-172, 2001.
11. J.-P. Vonsattel, R. H. Myers, T. J. Stevens, R. J. Ferrante, E. D. Bird, and E. P. Richardson Jr., "Neuropathological classification of huntington's disease," Journal of Neuropathology and Experimental Neurology, vol. 44, no. 6, pp. 559-577, 1985.
12. A. Crotti, C. Benner, B. E. Kerman et al., "Mutant Huntingtin promotes autonomousmicroglia activation viamyeloid lineagedetermining factors," Nature Neuroscience, vol. 17,no. 4, pp. 513-521, 2014.
13. D. A. Simmons,M. Casale, B. Alcon, N. Pham,N. Narayan, and G. Lynch, "Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease," Glia, vol. 55, no. 10, pp. 1074-1084, 2007.
14. S. F. Crocker, W. J. Costain, and H. A. Robertson, "DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations," Brain Research, vol. 1088, no. 1, pp. 176-186, 2006.
15. S. Franciosi, J. K. Ryu, Y. Shimet al., "Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease," Neurobiology of Disease, vol. 45, no. 1, pp. 438-449, 2012.
16. A. Silvestroni, R. L. M. Faull, A. D. Strand, and T. Möllera, "Distinct neuroinflammatory profile in post-mortem human Huntington's disease," NeuroReport, vol. 20, no. 12, pp. 1098-1103, 2009.
17. S.-Y. Chou, J.-Y. Weng, H.-L. Lai et al., "Expanded-polyglutamine Huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes," The Journal of Neuroscience, vol. 28, no. 13, pp. 3277-3290, 2008.
18. J. Bradford, J.-Y. Shin, M. Roberts, C.-E. Wang, X.-J. Li, and S. Li, "Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 52, pp. 22480-22485, 2009.
19. H.-Y. Hsiao, Y.-C. Chen, H.-M. Chen, P.-H. Tu, and Y. Chern, "A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in huntington's disease," Human Molecular Genetics, vol. 22, no. 9, Article ID ddt036, pp. 1826-1842, 2013.
20. S. Humbert, E. A. Bryson, F. P. Cordelières et al., "The IGF-1/Akt pathway is neuroprotective inHuntington's disease and involves huntingtin phosphorylation by Akt," Developmental Cell, vol. 2, no. 6, pp. 831-837, 2002.
21. E. Colin, E. Régulier, V. Perrin et al., "Akt is altered in an animalmodel ofHuntington's disease and in patients," European Journal of Neuroscience, vol. 21, no. 6, pp. 1478-1488, 2005.
22. N. Pavese, A. Gerhard, Y. F. Tai et al., "Microglial activation correlates with severity in Huntington disease: a clinical and PET study," Neurology, vol. 66, no. 11, pp. 1638-1643, 2006.
23. Y. F. Tai, N. Pavese, A. Gerhard et al., "Microglial activation in presymptomatic Huntington's disease gene carriers," Brain, vol. 130, no. 7, pp. 1759-1766, 2007.
24. M. Politis, N. Pavese, Y. F. Tai et al., "Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study," Human Brain Mapping, vol. 32, no. 2, pp. 258-270, 2011.
25. M. Politis, N. Pavese, Y. F. Tai, S. J. Tabrizi, R. A. Barker, and P. Piccini, "Hypothalamic involvement inHuntington's disease: an in vivo PET study," Brain, vol. 131, no. 11, pp. 2860-2869, 2008.
26. M. Politis, N. Lahiri, F. Niccolini et al., "Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers," Neurobiology of Disease, vol. 83, pp. 115-121, 2015.
27. Q. Fang, A. Strand, W. Law et al., "Brain-specific proteins decline in the cerebrospinal fluid of humans with huntington disease,"Molecular andCellular Proteomics, vol. 8, no. 3,pp. 451-466, 2009.
28. A. Dalrymple, E. J. Wild, R. Joubert et al., "Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates," Journal of Proteome Research, vol. 6, no. 7, pp. 2833-2840, 2007.
29. S. E. Jones and C. Jomary, "Clusterin," International Journal of Biochemistry and Cell Biology, vol. 34, no. 5, pp. 427-431, 2002.
30. P. B. Larkin and P. J. Muchowski, "Genetic deficiency of complement component 3 does not alter disease progression in amouse model of Huntington's disease," Journal of Huntington's Disease, vol. 1, no. 1, pp. 107-118, 2012.
31. C. Connolly, A. Magnusson-Lind, G. Lu et al., "Enhanced immune response toMMP3stimulation in microglia expressing mutant huntingtin," Neuroscience, vol. 325, pp. 74-88, 2016.
32. T. Vinther-Jensen, E. Budtz-Jørgensen, A. H. Simonsen, J. E. Nielsen, and L. E. Hjermind, "YKL-40 in cerebrospinal fluid in Huntington's disease-a role in pathology or a nonspecific response to inflammation" Parkinsonism and Related Disorders, vol. 20, no. 11, pp. 1301-1303, 2014.
33. S. M. Gollin, J. F. Leary, I. Shoulson, and R. A. Doherty, "Flow cytometric detection of lymphocyte alterations in Huntington's disease," Life Sciences, vol. 36, no. 7, pp. 619-626, 1985.
34. W. Kwan, U. Träger, D. Davalos et al., "Mutant huntingtin impairs immune cell migration in Huntington disease," Journal of Clinical Investigation, vol. 122, no. 12, pp. 4737-4747, 2012.
35. A. Weiss, U. Träger, E. J. Wild et al., "Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression," Journal of Clinical Investigation, vol. 122, no. 10, pp. 3731-3736, 2012.
36. U. Träger, R. Andre, N. Lahiri et al., "HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation," Brain, vol. 137, no. 3, pp. 819-833, 2014.
37. D. S. Barkley, S. I. Hardiwidjaja, W. W. Tourtellotte, and J. H. Menkes, "Cellular immune responses in Huntington disease. Specificity of brain antigenicity detected with huntington disease lymphocytes," Neurology, vol. 28, no. 1, pp. 32-35, 1978.
38. J. R. C. Miller, U. Träger, R. Andre, and S. J. Tabrizi, "Mutant huntingtin does not affect the intrinsic phenotype of human Huntington's disease T lymphocytes," PLoS ONE, vol. 10, no. 11, Article ID e0141793, 2015.
39. F. Leblhuber, J. Walli, K. Jellinger et al., "Activated immune system in patients with Huntington's disease," Clinical Chemistry and Laboratory Medicine, vol. 36, no. 10, pp. 747-750, 1998.
40. R. Wang, C. A. Ross, H. Cai et al., "Metabolic and hormonal signatures in pre-manifest and manifest Huntington's disease patients," Frontiers in Physiology, vol. 5, article 231, 2014.
41. E. Wild, A. Magnusson, N. Lahiri Swales et al., "Abnormal peripheral chemokine profile in Huntington's disease," PLoS Currents, vol. 3, Article ID RRN1231, 2011.
42. U. Träger, R. Andre, A. Magnusson-Lind et al., "Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models," Neurobiology of Disease, vol. 73, pp. 388-398, 2015.
43. J. Bouchard, J. Truong, K. Bouchard et al., "Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease," Journal of Neuroscience, vol. 32, no. 50, pp. 18259-18268, 2012.
44. N. A. Aziz, H. Pijl, M. Frölich, A. W. Maurits van der Graaf, F. Roelfsema, and R. A. C. Roos, "Leptin secretion rate increases with higher CAG repeat number in Huntington's disease patients," Clinical Endocrinology, vol. 73, no. 2, pp. 206-211, 2010.
45. N. P. Rocha, A. L. Teixeira, P. L. Scalzo et al., "Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease," Movement Disorders, vol. 29, no. 4, pp. 527-531, 2014.
46. U. Träger, A. Magnusson, N. Lahiri Swales et al., "JAK/STAT signalling inHuntington's diseaseimmune cells," PLoS Currents, 2013.
47. A. Khoshnan, J. Ko, E. E. Watkin, L. A. Paige, P. H. Reinhart, and P. H. Patterson, "Activation of the IκB kinase complex and nuclear factor-κB contributes to mutant huntingtin neurotoxicity," The Journal of Neuroscience, vol. 24, no. 37, pp. 7999-8008, 2004.
48. H. Kalonia and A. Kumar, "Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington's disease-like alterations in rats," Life Sciences, vol. 88, no. 17-18, pp. 784-791, 2011.
49. F. Norflus, A. Nanje, C.-A. Gutekunst et al., "Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice," Neurobiology of Disease, vol. 17, no. 2, pp. 319-325, 2004.
50. N. Garrido-Mesa, A. Zarzuelo, and J. Gálvez, "Minocycline: far beyond an antibiotic," British Journal of Pharmacology, vol. 169, no. 2, pp. 337-352, 2013.
51. C. Li, K. Yuan, and H. Schluesener, "Impact of minocycline on neurodegenerative diseases in rodents: a meta-analysis," Reviews in the Neurosciences, vol. 24, no. 5, pp. 553-562, 2013.
52. Huntington Study Group, "Minocycline safety and tolerability in Huntington disease," Neurology, vol. 63, no. 3, pp. 547-549, 2004.
53. M. Thomas, T. Ashizawa, and J. Jankovic, "Minocycline in Huntington's disease: a pilot study," Movement Disorders, vol. 19, no. 6, pp. 692-695, 2004.
54. V. M. Saito, R. M. Rezende, and A. L. Teixeira, "Cannabinoid modulation of neuroinflammatory disorders," Current Neuropharmacology, vol. 10, no. 2, pp. 159-166, 2012.
55. A. Curtis and H. Rickards, "Nabilone could treat chorea and irritability in Huntington's disease," Journal of Neuropsychiatry and Clinical Neurosciences, vol. 18, no. 4, pp. 553-554, 2006.
56. P. Consroe, J. Laguna, J. Allender et al., "Controlled clinical trial of cannabidiol in Huntington's disease," Pharmacology, Biochemistry and Behavior, vol. 40, no. 3, pp. 701-708, 1991.
57. B. S. Koppel, J. C. M. Brust, T. Fife et al., "Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology," Neurology, vol. 82, no. 17, pp. 1556-1563, 2014.
58. H.-Y. Hsiao, F.-L. Chiu, C.-M. Chen et al., "Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease," Human Molecular Genetics, vol. 23, no. 16, Article ID ddu151, pp. 4328-4344, 2014.
59. L. Dobson, U. Träger, R. Farmer et al., "Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells," Journal of Neurochemistry, vol. 137, no. 5, pp. 782-794, 2016.
60. A. L. Southwell, S. Franciosi, E. B. Villanueva et al., "Antisemaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128mouse model of Huntington disease," Neurobiology ofDisease, vol. 76,pp. 46-56, 2015.
61. Huntington StudyGroupTREND-HDInvestigators, "Randomized controlled trial of ethyl-eicosapentaenoic acid in huntington disease the trend-hd study," Archives of Neurology, vol. 65, no. 12, pp. 1582-1589, 2008.